Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

28 Jan 2005 16:48

Readybuy PLC28 January 2005 READYBUY PLC (the "Company") UNAUDITED INTERIM RESULTSFor the six months ended 31 October 2004 Chairman's Statement During the period under review, the Company has successfully secured several newlistings for its products with supermarkets. We have also started to produce ourproducts in reasonable volumes and now distribute to a number of customers bothon a regional and national basis. Certain lines have been listed on apromotional basis to build customer awareness. Results Turnover in the period under review was £139,000 producing a loss before tax of£138,000 and a loss per share of 0.8p As at 31 October 2004, the Group had net cash of approximately £51,000. Our monthly cash burn has been substantially reduced during this same period. Strategy We continue to pursue our stated strategy of developing a top quality range ofchilled ready meals both in the retail and food service sectors. We also intendto develop other products which will complement the existing portfolio. Staff As the business has grown, all our staff have worked extremely hard to meetcustomer requirements and I would like to thank them for all their efforts Prospects Since the half-year, we have been working on several new listings which have notyet been confirmed. Accordingly, the Directors believe that the results for thefull year will fall below market expectations. The board is currently reviewing its working capital requirements and may seekto raise additional equity to invest further in the business and to fund theGroup through to profitability. Colin DaviesNon Executive Chairman- READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 to 29/04/03 to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 TurnoverContinuing operations 139 19 0 Operating lossContinuing operations (137) (343) (114) Loss on ordinary activities before interest (137) (343) (114) Net interest (1) 0 0 Loss before taxation (138) (343) (114) Taxation 0 45 0 Loss after taxation (138) (298) (114) Dividends 0 0 0 Retained loss (138) (298) (114) Loss per shareBasic and diluted (0.8p) (2.2p) (1.2p) Dividends per share 0 0 0 READYBUY PLCGROUP BALANCE SHEETat 31 October 2004 Unaudited Audited Unaudited 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Fixed assetsGoodwill 629 646 671Tangible assets 208 218 212 837 864 883 Current assetsStock 17 7 0Debtors 116 82 52Cash at bank 276 429 659 409 518 711 Creditors falling due within one year (334) (323) (328) Net current assets 75 195 383 Total assets less current liabilities 912 1,059 1,266 Creditors falling due after one year (16) (25) (46) 896 1,034 1,220Capital and reservesCalled up share capital 90 90 90Share premium account 1,242 1,242 1,244Profit and loss account (436) (298) (114) Equity shareholders' funds 896 1,034 1,220 READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2004 Unaudited Audited Unaudited 6 months Period Period to 29/04/03 29/04/03 to to 31/10/2004 30/04/2004 31/10/2003 £'000 £'000 £'000 Operating loss (137) (343) (114) Depreciation and amortisation 33 82 42 Movement in working capital (17) (146) (163) Net cash outflow from operating activities (121) (407) (235) Net cash outflow from capital expenditure and financial investment (6) (42) (12) Purchase of subsidiary undertaking expenses and flotation - (272) (270) expenses Overdraft, net of cash, acquired with subsidiary undertaking - (6) (6) Net cash outflow from acquisitions and disposals - (278) (276) Net cash outflow before use of liquid resources and financing (127) (727) (523) Repayment of term loans - (220) (220) Capital element of finance lease payments (25) (19) (8) Issue of ordinary share capital net of redemption - 1,169 1,169 Net cash (outflow)/inflow from financing (25) 930 941 (Decrease)/Increase in cash in the period (152) 203 418 Analysis of net funds Cash at bank and in hand 276 429 659 Overdraft (225) (226) (241) 51 203 418 Debt repayable by instalments: Due within one year (18) (34) (24) Due after more than one year (16) (25) (46) (34) (59) (70) 17 144 348READYBUY PLCINTERIM ACCOUNTSfor the six months ended 31 October 2004 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2004 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985 2 The figures for the period ended 30 April 2004 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of the loss per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 17,994,010 (31 October 2003 9,295,367 and 30 April 2004 13,585,434). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20217:00 amRNSAffiDX Lateral Flow Test Detects Delta Variant
28th Jun 202112:13 pmRNSResult of AGM
21st Jun 20212:05 pmRNSSecond Price Monitoring Extn
21st Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSAffiDX Lateral Flow Test Distribution Agreement
15th Jun 20218:00 amRNSIssue of Equity and Total Voting Rights
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:07 amRNSRegistration of AffiDX Lateral Flow Test in EU
9th Jun 20219:08 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSMHRA Confirms Registration of Lateral Flow Test
1st Jun 20217:00 amRNSUpdate on Lateral Flow Test Regulatory Submissions
28th May 20217:00 amRNSResponse to speculation
25th May 202110:00 amRNSPosting of Annual Report and Notice of AGM
10th May 202110:36 amRNSAffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
6th May 20217:00 amRNSChange of Nominated Adviser
30th Apr 202112:37 pmRNSIssue of Equity
28th Apr 20215:18 pmRNSIssue of Equity
28th Apr 20214:41 pmRNSSecond Price Monitoring Extn
28th Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSFinal Results
20th Apr 202111:05 amRNSSecond Price Monitoring Extn
20th Apr 202111:00 amRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSClinical validation of AffiDX Lateral Flow Test
15th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:00 amRNSNotice of Results and Investor Presentation
12th Apr 20211:30 pmRNSIssue of Equity
6th Apr 20217:00 amRNSDistribution Agreement with ABCAM plc
25th Mar 20213:01 pmRNSDirectorate Change
16th Mar 20215:08 pmRNSIssue of Equity
15th Mar 20215:22 pmRNSIssue of Equity
9th Mar 20217:00 amRNSDiagnostic Licensing Deal with Biokit
8th Mar 20217:00 amRNSRapid Antigen Test Detects SARS-CoV-2 Variants
3rd Mar 20215:14 pmRNSElectronic Communications with Shareholders
24th Feb 20217:00 amRNSBusiness Update
22nd Feb 20217:00 amRNSRe: Press Speculation
18th Feb 20217:00 amRNSPhase I CTA for AVA6000 Approved by MHRA
16th Feb 20219:05 amRNSSecond Price Monitoring Extn
16th Feb 20219:00 amRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSResults of Initial Evaluation of SARS-CoV-2 LFT
8th Feb 20217:00 amRNSCommercial Partnership with Mologic
2nd Feb 20218:30 amRNSIssue of Equity
1st Feb 20217:00 amRNSAffyXell $7.3 Million Series A Financing
29th Jan 202111:00 amRNSIssue of Equity
28th Jan 20217:00 amRNSCollaboration Agreement with Bruker
7th Jan 20217:00 amRNSLicense Agreement with POINT Biopharma Inc.
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.